40 results on '"Li Zhang"'
Search Results
2. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC.
3. Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (INFORM; C-TONG 0804).
4. EGFR Mutation Testing Practices within the Asia Pacific Region.
5. A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer.
6. Autoimmune Diseases and Lung Cancer: A Mendelian Randomization Study.
7. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
8. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
9. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC.
10. Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
11. Table of Contents.
12. Table of Contents.
13. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
14. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
15. Table of Contents.
16. Table of Contents.
17. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
18. MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC.
19. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
20. Combined Model of Frameshift Mutations and Tumor Mutation Burden in Predicting Preliminary Response to Immune Checkpoint Inhibitors in NSCLC.
21. Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
22. Predictive Significance of Bone Sialoprotein and Osteopontin for Bone Metastases in Respectable Non-Small-Cell Lung Cancer:A Retrospective Study.
23. Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).
24. Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer.
25. Changes of Circulating Transforming Growth Factor-β1 Level During Radiation Therapy Are Correlated with the Prognosis of Locally Advanced Non-small Cell Lung Cancer.
26. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
27. Preliminary Investigation of the Clinical Significance of Detecting Circulating Tumor Cells Enriched from Lung Cancer Patients.
28. Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China.
29. An Alternative Approach to Determining Therapeutic Choices in Advanced Non-small Cell Lung Carcinoma (NSCLC): Maximizing the Diagnostic Procedure and the Use of Low-Volume Lung Biopsies.
30. Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
31. Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy.
32. Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia.
33. Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis.
34. Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.
35. A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
36. Table of Contents.
37. Table of Contents.
38. Interim safety results from the East/South East (E/SE) Asian subgroup of the open-label TRUST (TaRceva lUng cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer (NSCLC).
39. Predictive factors of efficacy and survival in Chinese non-small cell lung cancer patients treated with gefitinib.
40. Gefitinib versus chemotherapy as first-line treatment in elder patients with advanced non-small-cell lung cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.